Breaking News

Candel Therapeutics Acquires Next-Gen Drug Development Platform

High capacity herpes virus-based development platform and manufacturing expertise can be tailored to multiple tumor types and indications

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Candel Therapeutics, a developer of viral immunotherapies, has acquired all oncolytic and other Herpes Simplex Virus (HSV) based assets from PeriphaGen, Inc., bringing its vector engineering, production expertise and next-generation HSV drug development platform in-house. The acquisition expands Candel’s viral therapy leadership position and supports further development of Candel’s rQNestin34.5, currently in Phase I for recurrent malignant gliomas. Terms of the transaction were not d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters